Clinical Trial News and Research

RSS

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

BioMimetic Therapeutics, today announced highlights from its analyst and investor meeting which was held on Thursday, February 17 in San Diego, CA in conjunction with the American Academy of Orthopedic Surgery Annual Meeting.

18 Feb 2011

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Endo Pharmaceuticals and Bioniche Life Sciences Inc. today announced plans for peer-reviewed presentation of interim efficacy and safety results from the first Phase III trial of the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™ or EN3348.

18 Feb 2011

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

18 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

Two studies investigate frontiers of islet cell transplantation for treating diabetes

Two studies published in the current issue of Cell Transplantation investigate frontiers of islet cell transplantation for treating diabetes. Researchers in Milan, Italy re-examine the role of bone marrow stem cells in diabetic therapy and islet cell regeneration and Canadian researchers offer improved strategies for optimizing pancreatic islet culture in vitro.

18 Feb 2011

Loyola offers stem cell transplants to older patients with leukemia and lymphoma

As the first baby boomers turn 65, Loyola University Hospital has begun offering stem cell transplants to leukemia and lymphoma patients who previously were too old to qualify.

18 Feb 2011

Intrinsic initiates enrollment in Barricaid device clinical trial

Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid device.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Progenics Pharmaceuticals, Inc. today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen.

17 Feb 2011

1000th clinical trial added to Cancer Research UK's patient information website

Cancer Research UK has added the 1000th clinical trial to its award winning patient information website, CancerHelp UK, on the 10th anniversary of the launch of its clinical trials database today.

17 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire Pharmaceuticals, announced today financial results for the fourth quarter and year ended December 31, 2010. For the quarter ended December 31, 2010, the Company reported a net loss of $4.3 million, or per common share, compared to a net loss of $2.6 million, or per common share, for the same period in 2009.

17 Feb 2011

Researchers discover substance that reinforces brain's self-healing functions after stroke

The only acute treatment for a stroke currently available is thrombolysis. This uses drugs that dissolve the blood clot responsible for the stroke, but it only reaches around 10 per cent of stroke patients in time to prevent lasting damage. For other patients, there are no other effective drugs that reduce the loss of brain function following a stroke.

17 Feb 2011

Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

Genomic Health, Inc. today announced the presentation of two studies at the American Society of Clinical Oncology® (ASCO®) Genitourinary (GU) Cancer Symposium, including complete results from its prostate cancer gene identification study, which identified 295 genes strongly associated with clinical recurrence following radical prostatectomy with great consistency across multiple tumor samples examined in each patient.

17 Feb 2011

Virtual reality exposure therapy reduces PTSD symptoms in active military service members

An article published in a forthcoming issue of the Journal of Traumatic Stress is one of the first to provide evidence of the effectiveness of exposure therapy with active duty military service members suffering from posttraumatic stress disorder (PTSD). The study shows that virtual reality exposure therapy resulted in significant reductions in PTSD symptoms after an average of seven treatment sessions. Additionally, 62 % of patients reported clinically meaningful, reliable change in PTSD symptoms.

17 Feb 2011

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.

17 Feb 2011

Clinical trial finds atorvastatin may inhibit HIV progression, help in infection's management

A recent multicenter clinical trial of atorvastatin, a type of cholesterol-lowering drug, found that although the drug did not inhibit plasma HIV RNA levels, it did inhibit expression of cellular markers of immune activation and inflammation in patients with HIV infection.

17 Feb 2011

Study finds poor security practices in clinical trial file sharing methods

Patients who participate in clinical trials expect that their personal information will remain confidential, but a recent study led by Dr. Khaled El-Emam, Canada Research Chair in Electronic Health Information at the CHEO Research Institute, found that the security practices used to transfer and share sensitive files were inadequate.

17 Feb 2011

Sonablate HIFU device is now available in Brazil to treat prostate cancer

USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 medical device, announces that HIFU with the Sonablate is available to prostate cancer patients for the first time in Brazil at Hospital Nossa Senhora das Gracas in Curitiba, capital city of the state of Parana in southern Brazil.

17 Feb 2011

Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer

Oncolytics Biotech Inc. announced today that enrollment has begun in a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

17 Feb 2011

Clinical Trial News and Research

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Two studies investigate frontiers of islet cell transplantation for treating diabetes

Loyola offers stem cell transplants to older patients with leukemia and lymphoma

Intrinsic initiates enrollment in Barricaid device clinical trial

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

1000th clinical trial added to Cancer Research UK's patient information website

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Inspire fourth quarter revenues increase 2% to $30.3 million

Researchers discover substance that reinforces brain's self-healing functions after stroke

Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

Virtual reality exposure therapy reduces PTSD symptoms in active military service members

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

Clinical trial finds atorvastatin may inhibit HIV progression, help in infection's management

Study finds poor security practices in clinical trial file sharing methods

Sonablate HIFU device is now available in Brazil to treat prostate cancer

Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer